Cullinan Therapeutics Inc. (CGEM) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $14.93 (-0.66% 1D, market cap $967.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CGEM ranks #714 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $939.1M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).
Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $676.6M in revenue (+22.7% YoY), -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CGEM currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.65) and Max Pain ($15.68) forces dealer call-delta covering toward $24.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cullinan Therapeutics Inc. (CGEM) slipped -0.66% to $14.93, trading at 50% of its 52-week range ($6.73 – $23.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Cullinan Therapeutics reported that the U.S. FDA and Australian TGA cleared a global Phase 1b/2a trial of velinotamig in adults with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia,
Cullinan Therapeutics (CGEM) is back in focus after regulators in the U.S. and Australia cleared a global Phase 1b/2a trial of velinotamig in difficult immune thrombocytopenia and warm autoimmune hemolytic anemia. Cullin
Cullinan Therapeutics has more than doubled over the past year, which puts a sharp spotlight on whether that move still lines up with the strength of its balance sheet and book value. After a series of clinical updates,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +22.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CGEM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CGEM. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Cullinan Therapeutics Inc. (CGEM) ranks #714 by composite RQD confidence (32/100, grade E) and #359 by equity capitalization ($967.3M). Within this direct 5-issuer industry benchmark cohort, CGEM leads on earnings valuation at N/A trailing P/E, while CGEM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CGEM at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CGEM
ACTIVE
Cullinan Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -0.66% | $967.3M | Benchmark Subject |
| ODTX Odyssey Therapeutics Inc. | D | 46/100 | — | — | — | -0.05% | $939.1M | /odtx-vs-cgem → |
| GLUE Monte Rosa Therapeutics Inc. | E | 25/100 | — | — | -35.0% | -1.21% | $918.0M | /glue-vs-cgem → |
| MGTX MeiraGTx Holdings plc | E | 20/100 | — | — | -35.0% | -1.79% | $911.4M | /mgtx-vs-cgem → |
| INBX Inhibrx Biosciences Inc. | E | 18/100 | — | — | -35.0% | +0.53% | $1.06B | /inbx-vs-cgem → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cullinan Therapeutics Inc. (CGEM) reported GAAP revenue of $676.6M (+22.7% vs. FY2024 revenue of $551.4M , and +26.5% cumulative change since FY2023) , GAAP net income of -$219.9M, operating cash flow of -$175.8M, and free cash flow of -$175.8M (-21.0% YoY). On the balance sheet, CGEM closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $676.6M | -$219.9M | -$175.8M | -$175.8M | $448.4M | — |
| FY2024 (FY) | 2024-12-31 | $551.4M | -$167.6M | -$145.3M | -$145.3M | $621.8M | — |
| FY2023 (FY) | 2023-12-31 | $535.0M | -$155.1M | -$134.3M | -$134.3M | — | — |
As of 2026-11-03, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $14.93 (-0.66% 1D, market cap $967.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CGEM ranks #714 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $939.1M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).
Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $676.6M in revenue (+22.7% YoY), -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CGEM last traded at $14.93 (-0.66% on volume of 730,788 shares), positioning the stock -15.41% below its 50-day simple moving average ($17.65) and -5.80% below its 200-day simple moving average ($15.85). Across its 52-week range of $6.73 to $23.19, CGEM sits at the 49.8% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($13.15 to $16.71).
Cullinan Therapeutics Inc. (CGEM) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $14.93 (-0.66% 1D, market capitalization $967.3M).
Cullinan Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cullinan Therapeutics Inc. (CGEM) reported $676.6M in annual revenue (up from $551.4M in FY2024, +22.7% YoY) and -$219.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($535.0M revenue, -$155.1M net income) through FY2025, CGEM scaled operating cash flow to -$175.8M and free cash flow to -$175.8M, backed by $448.4M in total assets against $0 in total debt.
The source data therefore does not establish upstream or downstream dependencies, sector correlations, or second-order bottlenecks. The only sector context is the classification itself: Health Care, Biotechnology: Biological Products.
Real-time company headlines, analyst actions, and sector developments for Cullinan Therapeutics Inc. (CGEM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cullinan Therapeutics Inc. (CGEM) market action, institutional positioning, and fundamental catalysts.
Cullinan Therapeutics reported that the U.S. FDA and Australian TGA cleared a global Phase 1b/2a trial of velinotamig in adults with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia,
A cited BTIG Buy rating with a $41 price target sits against a $15.45 share price, per the news wire.. When you look under the hood at CGEM, Fundamental Cash Engine is 7/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $23.19. My 12M target is $19.09.
@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Free cash flow of -$175.8M in FY 2025 against $88.3M in cash, with ROIC of -35%, per the SEC financials and market data.. Look at the math on CGEM: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $13.23 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: